High-risk prostate cancer treated with a stereotactic body radiation therapy boost following pelvic nodal irradiation.

ABSTRACT:

Purpose

Modern literature has demonstrated improvements in long-term biochemical outcomes with the use of prophylactic pelvic nodal irradiation followed by a brachytherapy boost in the management of high-risk prostate cancer. However, this comes at the cost of increased treatment-related toxicity. In this study, we explore the outcomes of the largest cohort to date, which uses a stereotactic body radiation therapy (SBRT) boost following pelvic nodal radiation for exclusively high-risk prostate cancer.

Methods and materials

A large institutional database was interrogated to identify all patients with high-risk clinical node-negative prostate cancer treated with conventionally fractionated radiotherapy to the pelvis followed by a robotic SBRT boost to the prostate and seminal

SUBMITTER: Lischalk JW 

PROVIDER: S-EPMC10895712 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature